CG Oncology Holds 2025 Annual Stockholders Meeting

CG Oncology, Inc. ( (CGON) ) just unveiled an update.

On June 5, 2025, CG Oncology, Inc. held its 2025 Annual Meeting of Stockholders where key decisions were made regarding the company’s leadership and auditing practices. The stockholders elected three Class I directors to serve until the 2028 Annual Meeting and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (CGON) stock is a Buy with a $86.00 price target. To see the full list of analyst forecasts on CG Oncology, Inc. stock, see the CGON Stock Forecast page.

Spark’s Take on CGON Stock

According to Spark, TipRanks’ AI Analyst, CGON is a Neutral.

CG Oncology’s overall stock score reflects significant challenges in financial performance due to ongoing losses and reliance on external funding. However, the company’s strong equity position and recent positive clinical trial results provide potential upside. The technical analysis indicates a mixed trend, and valuation remains a concern with a negative P/E ratio. Investors should be cautious but also consider the potential long-term growth from successful product developments.

To see Spark’s full report on CGON stock, click here.

More about CG Oncology, Inc.

Average Trading Volume: 1,370,977

Technical Sentiment Signal: Sell

Current Market Cap: $2.03B

For an in-depth examination of CGON stock, go to TipRanks’ Stock Analysis page.